Accretive Health, Inc. announced that effective as of February 16, 2016, the following members of the company's Board of Directors resigned: Edgar M. Bronfman, Jr., Michael B. Hammond, Dr. Arthur Klein, Lawrence B. Leisure, Denis J. Nayden and Robert V. Stanek. Pursuant to the terms of the investor rights agreement and upon the recommendation of the nominating and corporate governance committee of the board, the board decreased the number of directors comprising the Board to nine and to fill the resulting vacancies, elected Joseph R. Impicciche as a Class III Director, John B. Henneman, III as a Class I Director and Neal Moszkowski, Ian Sacks and Anthony J. Speranzo as Class II Directors, each to serve until the 2016, 2017 or 2018 Annual Meeting, respectively, and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Henneman, 54, has more than 20 years of combined financial and operational management experience in the life sciences industry.

Since October 2014, Mr. Henneman has been the Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation. Mr. Impicciche, 57, has been the Executive Vice President and General Counsel of Ascension Health Alliance d/b/a Ascension, since the corporation's formation in September 2011. Mr. Moszkowski, 50, is a co-founder of TowerBrook Capital Partners L.P. and has served as the firm's co-chief executive officer since its inception in March 2005.

Mr. Sacks, 45, has been with TowerBrook Capital Partners L.P. since its inception in 2005. Previously, Mr. Sacks was with Soros Private Equity Partners. Mr. Speranzo, 67, has been the Executive Vice President and Chief Financial Officer of Ascension Health Alliance d/b/a Ascension, since the corporation's formation in September 2011.

From 2002 to September 2011, Mr. Speranzo served as the Senior Vice President and Chief Financial Officer of Ascension Health.